Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock
Alnylam’s second-quarter earnings report Thursday did little to assuage investor concerns in what has already been a difficult year for the company. The drugmaker lowered its full-year sales sales projection for ...
July 30, 2026 09:25 AM EDTUpdated 09:54 AM Pharma Alnylam cuts Amvuttra sales guidance as demand shifts, hurting stock Max Gelman Senior Editor Alnylam’s second-quarter earnings report Thursday did little to assuage investor concerns in what has already been a difficult year for the company. The drugmaker Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that